Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02605837 · ClinicalTrials.gov registry record · Phase 3
A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 318
- Enrollment target
NCT02605837 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 318 participants.
The verdict
NCT02605837, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 318 participants
- Enrollment target
Study Summary
A study in adolescents and adults with eosinophilic esophagitis (EoE) to measure the histologic response and determine if any reduction in dysphagia is achieved.
Interventions
- DRUG Placebo
- DRUG Oral Budesonide Suspension (OBS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 318 participants |
| Start Date | 2015-12-07 |
| Est. Completion | 2019-02-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02605837
The ClinicalTrials.gov registry entry for NCT02605837 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 318 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02605837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02605837 about?
NCT02605837 is a clinical study titled "A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved". A study in adolescents and adults with eosinophilic esophagitis (EoE) to measure the histologic response and determine if any reduction in dysphagia is achieved.
What is the current status of trial NCT02605837?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 318 participants. The study started on 2015-12-07. Estimated completion is 2019-02-15.
What interventions are being tested in trial NCT02605837?
The interventions under investigation include: Placebo (DRUG), Oral Budesonide Suspension (OBS) (DRUG).
Who is sponsoring clinical trial NCT02605837?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.